Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Age
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-08-10 5:15 PM EDT | Theralase Technologies Inc.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today re
Biotechnologies, Soins de santé et hôpitaux
2026-08-10 8:00 AM EDT | Envoy Medical, Inc.
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible par
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-08-07 5:25 PM EDT | Theralase Technologies Inc.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Recent Highlights Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Biotechnologies, Pharmaceutique
2026-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-06 4:05 PM EDT | Phio Pharmaceuticals Corp.
Noveris Health Sciences Inc. Unaware of Any Material Change
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. Noveris is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. A
2026-08-06 2:05 PM EDT | Noveris Health Sciences Inc.
AquaBounty Technologies Announces Expansion of Strategic Alternatives Review to Include Power Infrastructure Development Opportunities
Harvard, Massachusetts--(Newsfile Corp. - August 6, 2026) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty," "we," "our" or the "Company") today announced that it is expanding its ongoing strategic review process for its Pioneer, Ohio property to include opportunities related to power infrastructure and energy development. The Company has previously been engaged in efforts to monetize the Pioneer property through discussions with parties in the aquaculture industry. While th
Agriculture, Biotechnologies, Aliments / boissons
2026-08-06 8:30 AM EDT | AquaBounty Technologies, Inc.
Britannia Announces Normal Course Issuer Bid
Toronto, Ontario--(Newsfile Corp. - August 5, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announces that further to its news release dated May 21, 2026, the Company will commence a normal course issuer bid ("NCIB") to purchase for cancelation, from time to time over a 12-month period starting August 10, 2026, common shares ("Common Shares") of the Company in an aggregate amount of up to 8,112,717 Common Shares, representing 5% of Britannia's issued and outs
Biotechnologies, Produits ménagers / de consommation / cosmétiques, Santé, Fournisseurs de services auxiliaires liés au cannabis
2026-08-05 8:30 AM EDT | Britannia Life Sciences Inc
PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the "Prior News Releases"), it has closed a fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Offering"),
Biotechnologies, Pharmaceutique, Santé
2026-08-04 5:20 PM EDT | PreveCeutical Medical Inc.
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic partnership with Stealth Health (stealth.health), a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-08-04 7:00 AM EDT | Theralase Technologies Inc.
Telo Genomics Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange
2026-08-04 6:30 AM EDT | Telo Genomics Corp.
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026. As part of the leadership transitio
Biotechnologies, Pharmaceutique, Santé
2026-08-04 3:15 AM EDT | Defence Therapeutics Inc.
PharmaCorp Closes Previously Announced Ontario Pharmacy Acquisition and Provides Update
Saskatoon, Saskatchewan--(Newsfile Corp. -
Biotechnologies, Pharmaceutique, Commerce de détail
2026-07-31 2:45 PM EDT | PharmaCorp RX Inc.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe World Lung Cancer Day, BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company") proudly aligns with leading international healthcare organizations demanding equal access to early detection by developing simple, accessible blood testing that empowers patients and physicians with critical diagnostic insights when it matter
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-07-31 8:30 AM EDT | BioMark Diagnostics, Inc.
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05
Biotechnologies, Pharmaceutique, Santé
2026-07-30 5:57 PM EDT | Hemostemix Inc.
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-30 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Noveris Health Sciences Joins BioAlberta
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that it has become a member of BioAlberta, a not-for-profit industry association representing Alberta's life sciences community. BioAlberta supports its members through industry development, educational and networking activities, and engagement on matters affecting Alberta's life sciences sector. Its m
2026-07-30 5:05 PM EDT | Noveris Health Sciences Inc.
Therma Bright Inc. Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that further to its press release of June 23, 2026, it has now issued an aggregate of 6,613,999 common shares at a deemed price of $0.06 per share to settle aggregate debt of $396,840. All shares issued in relation to these debt settlements a
Technologies, Biotechnologies, Santé
2026-07-30 8:16 AM EDT | Therma Bright Inc.